Orphan drugs

The so-called 'orphan drugs' are intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions. The process from the invention of a replacement molecule to its marketing is long, expensive and really uncertain. Drugs that aren't developed by the pharmaceutical industry for economic reasons but which answer public health need. Actually, the indications of a drug can also be considered as ' orphan ' since a substance could also be utilized in the treatment of a frequent disease but might not are developed for an additional, more rare indication.


  • orphan drugs
  • pharmaceutical industry
  • Drugs
  • public health

Related Conference of Orphan drugs

November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
December 01-02, 2025

13th International Conference on Clinical Trials

Vancouver, Canada
January 29-30, 2026

19th World Drug Delivery Summit

Paris, France
February 10-11, 2026

40th World Congress on Pharmacology and Therapeutics

Barcelona, Spain
February 23-24, 2026

3rd World Congress on Biologics and Biosimilars

London, UK
March 23-24, 2026

36th Annual European Pharma Congress

London, UK
March 24-25, 2026

11th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
April 16-17, 2026

19th European Biosimilars Congress

Rome, Italy
April 27-28, 2026

9th European Biopharma Congress

Paris, Aland Islands
May 28-29, 2026

3rd International Conference on Pharmacognosy

Madrid, Spain
July 27-28, 2026

39th World Congress on Pharmacology

Rome, Italy

Orphan drugs Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in